We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Blood Test for Myocardial Infarction Tested

By LabMedica International staff writers
Posted on 19 Jun 2019
The level cardiac myosin-binding protein C (cMyC) in the blood increase more rapidly after a myocardial infarction, and to a higher extent, than troponin. More...
This means meaning that the new test can rule out a myocardial infarction in a higher proportion of patients straight away.

Under current UK guidelines, people suspected of having a myocardial infarction are tested for high blood troponin levels as soon as they arrive in an Accident and Emergency department (A&E), and again after three hours. Depending on the type of troponin test used, up to 85% of people will need to remain in hospital for further tests in order to rule out a heart attack.

An international team of scientists working with King’s College London (London, UK) took blood from 776 patients traveling to hospital by ambulance in Denmark. In patients who did experience myocardial infarction, the protein was present in high enough concentrations 95% of the time for an on-the spot diagnosis. Importantly, the cMyC test outperformed the existing troponin test, which was only capable of diagnosing around 40% of patients in this way.

The cMyC blood test, developed by a team from King’s College London and tested across Europe, has already been shown to rapidly rule out a heart attack in more people than the standard troponin test. The team hopes to work with industry to create a portable testing device to be used in UK A&E departments. The test could also be used in ambulances in countries where ambulances have to drive considerable distances to get patients to their nearest hospital. The press release states that a simple handheld device could replace the time-consuming processes involved in sending samples to the hospital labs for analysis.

Tom Kaier, MD, PhD, a lead author of the study, said, “It is important for both patients and doctors to work out early who has had a heart attack and who has not. Now that we know that this test is sensitive enough to give an almost immediate heart attack diagnosis, we need to work on developing a testing device. We’d love to see this used in A&E departments within the next five years.” The study was presented at the British Cardiovascular Society Conference held June 4-6, 2019, in Manchester, UK.

Related Links:
King’s College London


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.